• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis.

作者信息

van de Kerkhof P C M

机构信息

Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.

出版信息

Br J Dermatol. 2021 Nov;185(5):879. doi: 10.1111/bjd.20624. Epub 2021 Aug 17.

DOI:10.1111/bjd.20624
PMID:34402525
Abstract
摘要

相似文献

1
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis.接受司库奇尤单抗治疗的银屑病、银屑病关节炎和强直性脊柱炎患者的恶性肿瘤风险。
Br J Dermatol. 2021 Nov;185(5):879. doi: 10.1111/bjd.20624. Epub 2021 Aug 17.
2
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.司库奇尤单抗治疗银屑病、银屑病关节炎或强直性脊柱炎患者结核再激活的相关性。
JAMA Dermatol. 2021 Jan 1;157(1):43-51. doi: 10.1001/jamadermatol.2020.3257.
3
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.在欧洲真实世界环境中，司库奇尤单抗在中重度斑块状银屑病、银屑病关节炎和强直性脊柱炎患者中的应用：来自 SERENA 研究的基线数据。
Adv Ther. 2020 Jun;37(6):2865-2883. doi: 10.1007/s12325-020-01352-8. Epub 2020 May 6.
4
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.司库奇尤单抗治疗中重度斑块状银屑病、银屑病关节炎和强直性脊柱炎患者五年的长期安全性：汇总临床试验和上市后监测数据的更新。
Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563.
5
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.司库奇尤单抗治疗的银屑病、银屑病关节炎和强直性脊柱炎患者的恶性肿瘤风险：长达五年随访的临床试验和上市后监测数据的分析。
Br J Dermatol. 2021 Nov;185(5):935-944. doi: 10.1111/bjd.20136. Epub 2021 Jun 8.
6
Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: .司库奇尤单抗治疗附着点炎相关关节炎和银屑病关节炎的儿童和青少年患者： 。
Expert Rev Clin Immunol. 2024 May;20(5):435-440. doi: 10.1080/1744666X.2024.2303340. Epub 2024 Jan 10.
7
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.接受司库奇尤单抗治疗的银屑病、银屑病关节炎和强直性脊柱炎患者中炎症性肠病的发生率：21 项临床试验汇总数据的回顾性分析。
Ann Rheum Dis. 2019 Apr;78(4):473-479. doi: 10.1136/annrheumdis-2018-214273. Epub 2019 Jan 23.
8
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.司库奇尤单抗治疗银屑病、银屑病关节炎和强直性脊柱炎患者的持续性。
Farm Hosp. 2020 Dec 31;45(1):16-21. doi: 10.7399/fh.11465.
9
Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center.在 secukinumab 治疗期间新出现的炎症性肠病：来自一个三级中心的真实世界数据。
Rev Esp Enferm Dig. 2021 Dec;113(12):858-859. doi: 10.17235/reed.2021.8397/2021.
10
Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.类风湿关节炎、银屑病、银屑病关节炎或强直性脊柱炎患者每例生物反应调节剂的年度获得和管理成本。
J Med Econ. 2013 Sep;16(9):1120-8. doi: 10.3111/13696998.2013.820192. Epub 2013 Jul 18.